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Severe forms of hypertension are characterized by high blood
pressure combined with end organ damage. Through the devel-
opment and refinement of a transgenic rat model of malignant
hypertension incorporating the mouse renin gene, we previ-
ously identified a quantitative trait locus on chromosome 10,
which affects malignant hypertension severity and morbidity.
We next generated an inducible malignant hypertensive model
where the timing, severity, and duration of hypertension was
placed under the control of the researcher, allowing develop-
ment of and recovery from end organ damage to be investigated.
We have now generated novel consomic Lewis and Fischer rat
strains with inducible hypertension and additional strains that
are reciprocally congenic for the refined chromosome 10 quan-
titative trait locus. We have captured a modifier of end organ
damage within the congenic region and, using a range of bioin-
formatic, biochemical and molecular biological techniques,
have identified angiotensin-converting enzyme as the modifier
of hypertension-induced tissuemicrovascular injury. Reciprocal
differences between angiotensin-converting enzyme and the anti-
inflammatory tetrapeptide, N-acetyl-Ser-Asp-Lys-Pro in the kid-
ney,a tissuesusceptible toendorgandamage, suggestamechanism
for the amelioration of hypertension-dependent damage.
Malignant hypertension (MH)4 is a complex trait with both
genetic and environmental factors affecting development and
prognosis. Although improved diagnosis and preventative
medication has greatly reduced the incidence of MH (1–3), the
predisposing factors that trigger its onset are poorly under-
stood (4, 5). To gain insight into its genetic basis, we previously
generated a transgenic MH rat model, TGR(mRen2)27 (6), in
which the mouse Ren2 renin gene, driven by its endogenous
promoter, was incorporated into the Hanover Sprague-Dawley
rat (extensively reviewed; see Refs. 5 and 7–13). However, the
spontaneous and rapid (24–48 h) development ofMHbetween
50 and 90 days of age and heterogeneity of the outbred Sprague-
Dawley genetic background made the model unsuitable for
molecular dissection. Using informative crosses with Fischer
(F344) and Lewis (Lew) rat strains, the penetrance of and
survival from MH was found to be genetically determined
(14, 15). Resistance of the Lewis strain to the effects of highly
elevated blood pressure, and malignant hypertension sever-
ity was shown to involve an unknown modifier located
within the malignant hypertension severity quantitative trait
locus (QTL) on chromosome 10 (15).
To refine the experimental strategy, we placed themouse Ren2
renin cDNA under the control of an inducible cytochrome P-450
1a1 (Cyp1a1) promoter, on the Fischer (F344) genetic background
(Ren2.F), the transgene being integrated on the Y chromosome
(16). Judicious induction with the nontoxic xenobiotic indole-3-
carbinol (I3C) allowed the development of hypertension or transi-
tion to MH, the extent of end organ damage, and the repair pro-
cesses to be analyzed in detail (5, 11, 16–25).
Todeterminewhether the strain specific response tohighly ele-
vated blood pressure is due to the timing or extent of vascular
damage, a consomic rat strain was derived in which the inducible
transgene was maintained on the Lewis background. To investi-
gate the contributionof themodifier of endorgandamage (MOD)
to straindifferences,we alsoderived twocongenic strains inwhich
the reciprocal QTLs were introduced onto the consomic back-
grounds. These newly developed lines were used to determine the
genetic contributions of background strain and QTL to various
parameters of blood pressure, renal function, and end organ dam-
age.Using awide range of techniques, including reverse transcrip-
tion-PCR, Western blot, enzyme assay, and microarray analysis,
angiotensin-converting enzyme has been identified as a modifier
of end organ damage.
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EXPERIMENTAL PROCEDURES
Breeding Scheme for Generating Consomic and Congenic
Strains—Derivation of the consomic strain Ren2.L was per-
formedby amarker-assisted breeding program inwhichRen2.F
males (carrying the Ren2 transgene on the Y chromosome)
were backcrossed with Lewis females. Progenitors of each gen-
eration were selected by microsatellite genotyping with 125
markers chosen at 10–15 cM to provide coverage of all
autosomes.
Congenic strains, Ren2.F-MOD-L andRen2.L-MOD-F,were
also derived by a marker-assisted breeding program. In brief,
Ren2.F males and Lewis females were bred to produce F1 rats.
F1 males were backcrossed to either Lewis or F344 females to
produce the first backcross generation BC1-Lew or BC1-F344,
respectively. The males were genotyped for markers spaced
approximately every 15 cM. The optimal BC1-Lew male rats,
which were heterozygous F344/Lew for the MOD QTL region
but possessed the maximum Lew/Lew homozygosity for the
nonrelevant autosomal region of the genome,were selected and
backcrossed to Lewis females to produce each subsequent
backcross generation. From BC5, male progeny were geno-
typed only for markers spanning the MOD QTL region. After
12 backcross generations, males and females heterozygous for
F344/Lew in the reducedMODQTL regionwere brother-sister
mated to generate the homozygous congenic strain Ren2.L-
MOD-F, which carried the mouse Ren2 transgene on the Y
chromosome, was homozygous F344/F344 for the MOD QTL
region, but was homozygous Lew/Lew for the rest of the
genome. Congenic strain Ren2.F-MOD-L was generated by
repeated backcrossing to F344 females in an analogousmanner
to yield animals that were homozygous Lew/Lew for the MOD
QTL region but homozygous F334/F344 for the rest of the
genome (see Fig. 1a).
Treatment—The animal studies were undertaken under
United Kingdom home office license, following review by local
ethics committee.All of the ratswere housed individually, given
free access to water and standard commercial rat chow (Special
Diet Services, Witham, Essex, UK), and maintained under con-
trolled conditions of temperature (21  1 °C) and humidity
(50  10%), under a 12-h light/dark cycle. Animals (12–14
weeks old) from each strain were randomly divided into three
groups (8 rats/group). The animals from groups 1 and 2 were
given 100mg of I3C/kg of bodyweight/day by gastric gavage for
7 and 10 days, respectively. Control group 3 was gavaged with
carrier (vegetable oil).
Blood Pressure—Direct blood pressure of six animals in each
strain was monitored by radiotelemetry using surgically
implanted transmitters (Data Sciences International, St. Paul,
MN). The signal was decoded using Art 4.0 software, and sys-
tolic blood pressure, mean blood pressure, and diastolic blood
pressure data were collected.
Blood and Tissue Collection—The blood samples were col-
lected into potassium EDTA-coated microvette tubes for renin
assays, 1.5-ml Eppendorf tubes forAce activitymeasurement or
heparinized tubes containing captopril at 105 M final concen-
tration for measurement of N-acetyl-Ser-Asp-Lys-Pro (Ac-
SDKP). The samples for renin and Ac-SDKP measurement
were centrifuged at 4 °C for 6 min, and plasma was snap-frozen
and stored at70 °C prior to assay. The samples for Ace activ-
ity measurement were held for 2–3 h at room temperature and
then centrifuged at 1000  g for 10 min. The serum was col-
lected and kept at70 °C until use. At the end of the study, the
animals were killed by CO2 inhalation and cervical dislocation.
Tissues including lung, left kidney, and liver were immediately
frozen in dry ice and stored at80° until use. Tissues including
mesentery, heart, pancreas, and right kidney were fixed in 10%
neutral buffered formalin for pathological examination and
immunohistochemical analysis.
Plasma Renin Activity Determination—Plasma renin activity
was measured by a modification of the method described pre-
viously (26). Aliquots of plasma were incubated at 0 and 37 °C
for 30min with angiotensin I (Ang I) antiserum (a generous gift
of Dr J. J. Morton, University of Glasgow) in Tris buffer (pH 7.4,
50 mM). The Ang I generated and trapped was measured by
radioimmunoassay. Plasma renin activity values are given as ng
of Ang Ih1ml1.
Renal Function Study—The animals were anesthetized (120
mg of inactin/kg intraperitoneally) and prepared for renal func-
tion studies as previously described (27). The rats were infused
intravenously with a saline solution containing 0.5% para-
amino hippuric acid and 0.5% fluorescein isothiocyanate-inulin
for measurement of renal plasma flow (RPF) and glomerular
filtration rate (GFR) respectively. After a 1-h equilibration
period, urine was collected for 60 min, and blood (200 l) was
collected before and after. The concentration of para-amino
hippuric acid and fluorescein isothiocyanate-inulin weremeas-
ured in urine and plasma by colorimetry and fluorimetry,
respectively.
Histological Examination and Immunohistochemical Anal-
ysis—Mesentery, pancreas, kidney, and heart were evaluated
formicrovascular changes using conventional hematoxylin and
eosin and periodic acid-Schiff-stained 3-m histologic sec-
tions. The sectionswere scored blind to the experimental group
and time point. In the heart, necroinflammatory lesions were
counted in sequential transverse sections comprising left ven-
tricle, interventricular septum, and right ventricle. For other
organs, the severity of arterial microvascular changes was eval-
uated on a 5-point ordered categorical scale for reactivemyoad-
ventitial changes (scoring 1 or 2 by severity and prevalence) and
destructive mural lesions that are a hallmark lesion of malig-
nant phase hypertension (scoring 3–5 according to prevalence;
see supplemental Fig. S3). Myoadventitial expansion with
mononuclear cells and myofibroblasts was associated with
medial changes of myocyte enlargement, amphophilic cyto-
plasmic staining, nuclear enlargement, occasional mitoses,
and, in the most severe examples, apparent myocyte disar-
ray. Hallmark destructive changes were characterized by evi-
dence of intramural contiguous cell death (necrosis) and/or
fibrinoid change. For statistical evaluations the groups were
compared nonparametrically, on the basis of the presence or
absence of hallmark destructive vascular changes (score 3–5
inclusive), so error bars are inappropriate.
Immunohistochemistry for Ace protein used mouse anti-
Acemonoclonal antibody (MAB3502;Chemicon International,
1:125 dilution). De-waxed and rehydrated paraffin sections (3
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m) underwent antigen retrieval in a microwaveable pressure
cooker for 2.5 min at pressure before incubation with primary
antibody solution for 30min at room temperature. Bound anti-
body was labeled and visualized using the DAKO Envision 
system horseradish peroxidase kit, before counterstaining sec-
tions with Mayer’s hematoxylin. Negative control slides omit-
ted the primary antibody.
Microarray Analysis—Gene expression profiles from kidney
RNA of Ren2.F, Ren2.L, Ren2.F-MOD-L, and Ren2.L-MOD-F
were analyzed at 0, 7, and 10 days after induction. Four biolog-
ical replicates were used for each condition. The left kidneys
were dissected, and both fat and kidney capsules were removed.
The kidneys were quartered, transferred to 2-ml Eppendorf
tubes, snap frozen in liquid nitrogen, and stored at 80 °C.
Total RNAwas extracted (TRIzol reagent; Invitrogen), purified
(RNeasy Mini kit; Qiagen), and DNase I-treated (RNase-Free
DNase Set; Qiagen), according to the manufacturers protocols.
RNA concentration and purity was determined with a Nano-
Drop ND-1000 spectrophotometer (NanoDrop Technologies,
Wilmington, DE) and Agilent 2100 Bioanalyser (Agilent Tech-
nologies, SantaClara, CA). RNA sampleswere immediately fro-
zen and stored (80 °C). Biotin-labeled targets for themicroar-
ray experiment were prepared using 1 g of total RNA.
Ribosomal RNA was removed with the RiboMinus human/
mouse transcriptome isolation kit (Invitrogen), and cDNA was
synthesized using the GeneChipwhole transcript sense target
labeling and control reagents kit (Affymetrix, Santa Clara, CA).
5 g of biotinylated target was hybridized with the GeneChip
rat exon 1.0 ST array (Affymetrix) at 45 °C for 16 h. After wash-
ing, specifically bound target was detected using the GeneChip
hybridization, wash and stain kit, and the GeneChip Fluidics
Station 450 (Affymetrix). The arrays were scanned using the
GeneChip Scanner 3000 7G (Affymetrix), and CEL intensity
files were produced usingGeneChip operating software version
1.4 (Affymetrix). CEL files were analyzed in Bioconductor using
the OneChannelGUI package. Robust multi-array average
sketch was used to generate probe summaries using the
extended probe set for the gene and exon level. Limmawas used
to generate raw p values, and the Benjamini andHochberg pro-
cedure was used for multiple testing corrections. Genes with a
corrected p value less than 0.05 were classed as differentially
expressed.
Bioinformatics Analyses—The Ensembl (28) data base
(release 46) was mined with the BioMart tool to identify genes
in the MOD locus. The positions of markers D10Rat15 and
D10Rat142 were used to limit a search on rat chromosome 10.
Gene identifiers, symbols, descriptions, and ontology informa-
tion were extracted to help identify genes of interest. The name
and symbol of each gene were concatenated to generate a gene
query string (for example, “Mapt or microtubule-associated
protein tau”). These strings were used to query the Pubmed
data base via Pubmatrix (29) for co-citation with relevant terms
(including hypertension, kidney, renal, vasculature, and pathol-
ogy). In addition, gene expression profiles were inferred by
using data from Unigene, Gene Expression Omnibus, and
Array Express as appropriate.
Quantitative Real Time PCR—Total RNA was extracted
from tissues using TRIzol reagent (Invitrogen). The RNA was
treated with DNA-Free (Ambio, Austin TX) and quantified,
and its integrity confirmed by gel electrophoresis. RNA (3 g)
was reverse transcribed, using a SuperScript II first strand
cDNA synthesis kit (Invitrogen). The resultant cDNA was
amplified by TaqMan real time quantitative PCR on either the
ABI Prism 7000 sequence detection system (Applied Biosys-
tems, Warrington, UK) or the LightCycler 480 real time PCR
system (RocheApplied Science). (The PCR primers are given in
supplemental Table S3.) The reactions were carried out in trip-
licate and normalized to 18 S for the samples from kidney and
wbscr1 for samples from liver.
Western Blot—The kidney samples were homogenized, and
proteins were extracted for Western blot analysis exactly as
described (30).
AceActivityAssay—SerumAce activitywasmeasuredusing a
commercial kit (Alpha Laboratories, Eastleigh, UK) adapted for
use on the Cobas Fara Centrifugal analyzer (Roche Applied Sci-
ence). The in vivo activity of Ace was tested in cohorts of non-
induced Ren2.L (n  5) and Ren2.F (n  5) rats by measuring
the pressor response to bolus injections of Ang I (2.5, 5, 10, 20,
40, and 80 ng). The peptide was injected in 0.1 ml of saline at
10–15-min intervals; injection of saline alone had no effect on
MABP. Pressor responses to Ang I were abolished by prior
injection of captopril (3 mg/kg), thereby confirming Ace as the
principal route of acute angiotensin II generation.
Tissue Ace Activity and Km Determination—Tissue Ace
activity was assayed by an adaptation of themethod of Santos et
al. (31), replacing serum with tissue, homogenized in ice-cold
lysis buffer (30 mM KCl, 0.25 M sucrose, 1% Triton X-100), and
spun to remove cell debris (500 g; 15 min; 4 °C), utilizing the
tripeptide Hip-His-Leu (Sigma) as substrate. Fluorescence
(excitation, 355 nm; emission, 460 nm) of the dipeptide product
was measured in duplicate samples using a 1420 Multilabel
HTS counter (PerkinElmer Life Sciences) and adjusted accord-
ing to protein concentration. Ace activity is expressed as mM
His-Leu/g of protein/h at 37 °C.
For Km determination, 1 l of lung extract was incubated
with various concentrations of Hip-His-Leu substrate (0.1, 0.2,
0.3, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 4, and 5 mM) for 15 min, respec-
tively. The hydrolysis ofHip-His-Leuwasmeasured by fluorim-
etry as described above. The Km was calculated by nonlinear
regression analysis (using Graphpad Prism).
Plasma and Tissue Ac-SDKP Measurement—Ac-SDKP con-
centration was measured after cold methanol extraction of
plasma or tissue homogenate (32) by a competitive enzyme
immunoassay (Spi Bio, Massy, France) according to the manu-
facturer’s protocol. The results are presented as pmol
Ac-SDKP/mg extracted protein (as determined by BCAprotein
assay kit; Pierce).
Statistical Analysis—The measurement data are summa-
rized with the means  S.E. Statistical comparison of means
wasmade using t test or ANOVA followed by Bonferroni’s post
hoc test. The ordered categorical pathologic scores of tissue
microvascular injury were analyzed with Fisher’s exact proba-
bility test (one tailed) or with Chi square tests, comparing for
the presence or not of destructive vascular lesions. p 0.05 was
judged to indicate significance.
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RESULTS
Development of Consomic and Congenic Strains—The
strategy by which the Y chromosome-linked inducible renin
transgene was introduced onto the Lewis (L) genetic back-
ground (Ren2L) is outlined in Fig. 1a. Development of the
congenic strains, Ren2.F-MOD-L, in which a greatly reduced
Lewis QTL is present on the F344 background, and Ren2.L-
MOD-F incorporating the reciprocal QTL region, is also
shown (Fig. 1a). The extent of each congenic region was
ascertained using microsatellites (Fig. 1b). The maximum
limit of the smaller congenic region (in Ren2F-MOD-L) was
found to be 4.0 Mb. A survey of informative single nucle-
otide polymorphisms within the QTL failed to reduce this
region further (data not shown).
FIGURE 1.Production of the congenic strains andmapping of theMODQTL. a, Ren2.Fmales and Lewis femaleswere bred to produce F1 animals. F1males
were backcrossed to Lewis or F344 females, respectively, for 12 generations, the choice of male at each generation being marker-assisted. Brother-sister
matings produced Ren2F-MOD-L and Ren2L-MOD-F strains. b, the extent of the congenic region on chromosome 10 (hatched box) was determined using
informative microsatellites and further refined (black box) by scanning informative single nucleotide polymorphisms with high resolution melting analysis.
FIGURE 2. Transgene expression in consomic and congenic lines before and after induction, and telemetric analysis ofmean arterial blood pressure (n
6/group/experiment).a, plasmaactive renin.b,mouseRen2expression in the liver, relative towsbcr1expression.c, centralpanel shows thedailymeanarterialblood
pressures for 5daysprior to inductionand for the10-daydurationof induction. Left panel, variation inMABPbetweenstrainsprior to induction.Right panel, change in
MABP during induction. **, p 0.01 versus parental consomic. Ren2.L is shown as a dotted line, and the other groups aremarked as per the key.
AceModifies End Organ Damage
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Transgene-derived and Endogenous Renin Expression—
Plasma active renin levels were similar in the four rat strains
prior to induction and, importantly, were increased by equiva-
lent amounts throughout induction (Fig. 2a). There was no
mouse renin mRNA detectable in the liver prior to induction
(by reverse transcription-PCR analysis), but there was strong
induction at day 7 and 10, with no statistical difference between
strains at any time point (Fig. 2b). Endogenous rat renin levels
in the kidney were suppressed by induction of the transgene
(supplemental Fig. S1).
Effect of I3C Induction on MABP—The MABP of all strains
was monitored before and during induction, and daily averages
are presented (Fig. 2c, central panel). (For systolic and diastolic
data see supplemental Fig. S2.) Prior to induction the MABP
was significantly higher in Ren2.F and Ren2F-MOD-L than in
Ren2.L and Ren2L-MOD-F, respectively (Fig. 2c, left panel),
indicating that the background genotype rather than that of the
congenic QTL region largely determines basal blood pressure.
After transgene induction, blood pressure increased in all
groups of rats (Fig. 2c, central panel; effect of induction p 
0.001; 2-way ANOVA), which was again influenced by geno-
type (Interaction p 0.001). The increase inMABP was signif-
icantly greater in Ren2.F than Ren2.L with congenic strains
achieving levels intermediate between the two consomic
strains. Because preinduction blood pressures were not equiv-
alent, theMABPs following inductionwere compared (Fig. 2c,
right panel). This analysis revealed that the MOD QTL, rather
than background genotype, determines the hypertensive
response to transgene induction. The fall in blood pressure in
Ren2.F animals at day 10may reflect onset of renal/heart failure
as suggested by histological examination (see below).
Effect of I3C Induction on Body Weight—The Ren2.F and
Ren2.L-MOD-F animals showed clinical signs of severe hyper-
tension, including weight loss, by day 3, and their condition
deteriorated over the induction period (with average weight
loss of 10% after 7 days; data not shown). However the Ren2.L
and Ren2.F-MOD-L animals showed no obvious clinical signs
of severe hypertension under the same induction. This suggests
that the propensity toward severe hypertension segregates with
the MOD QTL.
Effect of I3C Induction on Tissue Pathology—Pathologic
changes in the heart (necroinflammatory lesions) were
counted, and changes in the microvasculature of kidney, mes-
entery, and pancreas were scored for the prevalence and degree
FIGURE 3. Pathological assessment of strains after induction in mesentery (a), pancreas (b), and kidney (c) is shown. The severity of microvascular injury was
estimatedwith a 5-point ordered categorical scale according to the presence of reactivemyoadventitial changes only (scoring 1 or 2 if widespread and severe)
or additional destructive lesions, characterized by intramural necrosis and/or fibrinoid change (scoring 3–5 for a single focus, 2–3 foci, or 	3 foci/section,
respectively). In the heart (d), severity was the mean count of necroinflammatory lesions (NI) in interventricular septum, left and right ventricle per cardiac
transverse section. e, mesentery: small artery showing reactive myoadventitial changes: plump reactive medial myocytes and disarray, merging with adven-
titial proliferation andmononuclear inflammatory cell infiltration (approximatemagnification,40). f, kidney: small artery showing a destructive lesion. There
is mild adventitial proliferation and mononuclear cell infiltration surrounding a media with coagulative necrosis, intramural hemorrhage, and luminal endo-
thelial hypertrophy (60). g, heart, showing a necroinflammatory lesion affecting a right ventricular papillary muscle, with central coagulative necrosis, a
surrounding mononuclear cell infiltrate and myofibroblastic proliferation (20).
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of reactive myo-adventitial changes and destructive mural
lesions characteristic of malignant hypertension. Typical histo-
logical sections are shown, and the scoring is summarized
graphically (Fig. 3; see also supplemental Fig. S3 for additional
histological sections anddetailed description of pathology scor-
ing). Despite evidence of pancreatic damage, the Ren2.L con-
somics and Ren2.F-MOD-L congenics showed the mildest
effects of microvascular damage after transgene induction. The
presence of hallmark destructive microvascular lesions in
the different tissues correlated significantly with genotype at the
MODQTLand suggested that by 10 days of induction, themost
severely affected Ren2.L-MOD-F and Ren2.F animals might be
suffering heart failure (as evidenced by the fall in blood pres-
sure). The pathologic changes were not simply a function of the
absolute level of hypertension, because the tissue pathology in
Ren2.L-MOD-F was more severe than that in the reciprocal
congenic Ren2.F-MOD-L (mesentery, 7 days, p  0.0039; kid-
ney, 7 days, p  0.017; and heart, 10 days, p  0.01), despite
similarly induced blood pressures. It is possible that the larger
MABP (in the Ren2.L-MOD-F group) from a lower base line
may determine the subsequent severity of the MH pathology.
(Earlier evidence (15) suggests that carrying Fischer genes at the
chromosome 10 QTL in conjunction with Lewis genes at a sec-
ond QTL on chromosome 17 (LOD3.9) had a multiplicative
detrimental effect on mortality in TGR(mRen2)27 rats. It is
possible that the chromosome 17 QTL contributes to severity
of end organ damage in the Ren2.L-MOD-F consomic strain.)
Effect of I3C Induction on Renal Hemodynamics—Hyperten-
sive end organ damage is characterized by renal vasocon-
striction that contributes to ische-
mia and ultimately organ failure.
Under noninduced conditions,
there was a significant effect of
background genotype on base-line
renal hemodynamics; bothRPF (Fig.
4a; p  0.001; ANOVA) and GFR
(Fig. 4c; p  0.05 ANOVA) were
lower in Ren2.F than Ren2.L. These
differences were not determined by
the MOD locus, because neither
congenic was different from its
parental strain.However, the degree
of reduction in RPF that occurred
after induction of hypertension cor-
responded to MOD QTL rather
than background genotype (Fig. 4b).
Qualitatively, the same genotype-
phenotype relationships were also
evident for GFR (Fig. 4d), but the
effect of transgene induction ap-
peared muted, possibly because of
autoregulation of kidney filtration
processes.
Microarray and PCR Analysis of
Genes in QTL—Because Ren2.F-
MOD-L exhibited ameliorated phe-
notype compared with Ren2.F, the
MOD QTL region of 4.2 Mb must
still retain the gene(s) responsible for the strain difference.
Genome searches using Ensembl (RGSC 3.4, Dec 2004 genome
build) revealed that the QTL spans 64 genes: 48 known genes
(the best annotation status in Ensembl where each gene has a
full-length cDNA for that species)/four “known by projection”
genes/six predicted (all short noncoding RNA genes)/six novel
genes. Microarray analysis allowed us to compare expression
patterns of 43 of these genes, which were represented by good
transcript clusters on the rat exon array in the extended probe
set. (Sixteen other genes were represented by ambiguous tran-
script clusters, and five genes had no probes; see supplemental
Table S1.) Of the 43 genes, only Ace was significantly differen-
tially expressed in a QTL-dependent fashion. By literature
mining for co-citation with relevant terms of interest
(including hypertension, kidney, renal, vasculature, and
pathology) and consideration of gene expression profiles
(where known), we independently identified 17 genes as
potential candidate genes within the QTL (Fig. 5a), and these
genes were assessed by reverse transcription-PCR. Although
some were differentially expressed on the basis of back-
ground genotype (supplemental Table S2), most showed no
difference between strains. Only kidney Ace expression
clearly followed the MOD QTL, a difference that was main-
tained during induction (Fig. 5b).
Characterization of Ace—Serum Ace activity (Fig. 6a) and
Western blot analysis (Fig. 6b) revealed that both Ace activity
and Ace protein are lower in noninduced Ren2.L than Ren2.F.
Likewise, in vivo assessment of Ace function demonstrated sig-
nificantly lower activity (p  0.001; ANOVA) in Ren2.L rats
0
FIGURE 4. Renal hemodynamics were assessed before and following 7-day induction, by measuring renal
clearance of para-amino hippuric acid and fluorescein isothiocyanate-inulin (n 6/group/experiment) non-
inducedRPF (a),RPF after 7 days induction (b), noninducedGFR (c), andGFR after 7 days induction (d). *, p
0.05; **, p 0.01 versus parental consomic. Dark gray, Ren2.F; black, Ren2F-MOD-L; light gray, Ren2.L-MOD-F;
white, Ren2.L).
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than in Ren2.F (Fig. 6c). The similarity of EC50 of the two activ-
ity curves (Fig. 6c) suggests that the intrinsic catalytic activities
are comparable, and the Km of kidney Ace was found to be
equivalent in Ren2.F and Ren2.L, using a synthetic substrate
(1.139 0.112 versus 1.055 0.144 mM; p 0.002). Immuno-
histological examination could not resolve differences in endo-
thelial staining for Ace in target tissues between the consomic
and congenic strains.
Characterization of Ac-SDKP—It has been shown that the
N-terminal domain of Ace is able to cleave Ac-SDKP (33,
34), a naturally occurring tetrapeptide recently found to pre-
vent and reverse inflammation, cell proliferation, and fibro-
sis in various rat models of hypertension (35, 36). Although
neither plasma nor lung tetrapeptide levels differed between
Fischer and Lewis animals (plasma, 2.61 0.23 versus 2.28
0.27, p 0.34; lung, 6.73 0.55 versus 5.23 1.32, p 0.27),
kidney levels of Ac-SDKP were found to be significantly
lower in Fischer than Lewis ani-
mals (8.27  0.34 versus 9.98 
0.35, p  0.005).
DISCUSSION
The analysis of consomic and
congenic lines clearly shows that the
degree of hypertension and severity
of pathophysiological changes in
MH is modified by gene(s) within
the chromosome 10QTL. Given the
ambiguity of transcript clusters and
the lack of probe sets, it is not tech-
nically possible to assay all 64 genes
across the QTL by the currently
available microarrays. We therefore
used literature mining and expres-
sion profiles to independently iden-
tify possible candidate genes. These
independent processes converged
on Ace as the modifier gene respon-
sible. We cannot exclude the possi-
bility that an additional gene or
genes within the QTL may contrib-
ute to the effect. To unequivocally
confirm Ace as the sole modifier, it
would be necessary to convert Fis-
cher Ace to Lewis Ace by gene tar-
geting, but this is not readily achiev-
able in the rat as yet.
Ace is a powerful regulator of vas-
cular function in multiple tissues,
and evidence from widely different
sources supports our results. Inhibi-
tion of the renin-angiotensin-aldo-
sterone system in hypertension is
clinically beneficial, yet the reduc-
tion in cardiovascular morbidity
and remodeling is independent of
the antihypertensive effect (37).
Increased mouse Ace gene copy
number does not affect blood pressure per se but exacerbates
hypertension caused by additional environmental or genetic
factors (38). In human population association studies, the gen-
otype of ACE has been shown to predispose individuals to MH
(39, 40). Treatment of TGR(mRen27) rats with subhypotensive
levels of the Ace inhibitor ramipril specifically reduced tissue
Ace and prevented the development of end organ damage (41)
despite the increase in blood pressure associated with chronic
expression of the transgene. This strongly implicated Ace or
Ang II in the pathophysiological development of MH.
Previous studies on Ren2.F demonstrate that RPF decreases
following I3C induction and that plasma and intrarenal Ang II
levels increase (despite reduced levels of endogenous renal
renin). All of these effects are prevented by the administration
of the angiotensin II receptor type 1 receptor antagonist cande-
sartan (21). Mineralocorticoid receptor blockade by spirono-
lactone alleviates proteinuria following I3C induction but has
FIGURE 5. a, candidate genes, lyingwithin or just outside the congenic region defined in Ren2.F-MOD-L. b, Ace
mRNAexpression in consomic andcongenic strains (expressedas arbitraryunits relative to18S) innoninduced
kidney (panel i) and following 7 (panel ii) or 10 days induction (panel iii). *, p 0.05; **, p 0.01; ***, p 0.001
versus parental consomic (n 6).
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little effect on systolic blood pressure, suggesting that the ele-
vated arterial blood pressure (but not necessarily end organ
damage) is independent of aldosterone stimulation (23). The
basal (uninduced) differences in RPF andBP between consomic
and congenic strains indicate that renal vascular resistance is
higher on the Fischer than Lewis background. Intrarenal renin-
angiotensin-aldosterone levels will contribute to this, but the
basal strain difference results from the integration of multiple
vasoactive systems (42). Amajor determinant of renal hemody-
namic function was previously identified on chromosome 1
(43).We have now shown that Ace affects RPF following induc-
tion of hypertension.
The increased Ace protein levels in Ren2.F compared with
Ren2.L parallel increased renal mRNA levels in the prehyper-
tensive state, the cause of which remains to be elucidated, but it
could reflect differences in regulation of transcription (44) or
feedback regulation. Comparison of Lewis and F344 cDNA
sequence reveals three base changes in the coding region, twoof
which are conservative. The third
causes an amino acid substitution
(L341F) in the N-terminal domain,
which, by comparison to a three-di-
mensional model of the human
N-terminal domain (with a compet-
itive inhibitor molecule bound) (45)
(supplemental Fig. S4), lies at the
hinge between two helices. Model-
ing suggests that amino acid substi-
tution in this loopwould have only a
minor effect on overall three-di-
mensional structure (supplemental
Fig. S4). Studies of mice with spe-
cific inactivation of either the N or
C-terminal domain suggest that
the C-terminal rather than the
N-terminal domain plays a major
role in normal blood pressure con-
trol (33, 46). This may be the rea-
son why measurement of in vivo
ACE activities (with endogenous
Ang I substrate) and Km analyses
(using the synthetic tripeptide
substrate) yielded comparable
results between Lewis and Fischer
samples.
The N-terminal domain of
human Ace has been shown to
specifically cleave the naturally
occurring peptide, Ac-SDKP,
whereas specific inactivation of
themouse Ace N-terminal domain
causes an accumulation of
Ac-SDKP in plasma and urine
(33). The tetrapeptide has recently
been shown to act directly on bone
marrow stem cells and macro-
phages, inhibiting their differenti-
ation, activation, and cytokine
release (47). Interestingly, the levels of Ac-SDKP were found
to be raised in the kidney (an end organ damage-susceptible
tissue) in Lewis compared with Fischer animals but not in
the relatively damage-resistant lung. The reciprocal nature
of tissue Ace and Ac-SDKP levels in susceptible tissues of
Fischer and Lewis strains may explain the moderation of end
organ damage in the latter strain. Using the N-terminally
specific tetrapeptide substrate, both Ace activity and cata-
lytic properties have been reported to be identical in both
Lewis and Fischer strains (48).
Wehypothesize that reduced efficiency ofAc-SDKPcleavage
caused by reduced levels ofAceper semay ameliorate endorgan
damage through the anti-inflammatory effects of increased lev-
els of tissue-specific tetrapeptide. The identification of Ace as a
modifier of MABP, RPF, and hypertensive end organ dam-
age suggests that ACE levels should be a consideration in dis-
cerning susceptibility to essential hypertensive tissue damage
and MH in humans.
FIGURE 6. a, serum Ace activity in noninduced animals (panel i) or following 7 (panel ii) or 10 days induction
(panel iii). *, p  0. 05; **, p  0.01; ***, p  0.001 (n  6). b, panel i, Western analysis shows the relative
expression of ACE in kidney between Fischer (tracks 1–6) and Lewis (tracks 7–12) rats. The upper panel shows
immunoblot using ACE antibody, and the lower panel shows glyceraldehyde-3-phosphate dehydrogenase
loading control.Panel ii, proteinquantificationbydensitometry. The ratio of themeansS.E. is shown (***,p
0.001). c, the dose-response pressor effect of angiotensin I in cohorts of noninduced Ren2.F (gray line; n 5)
and Ren2.L (dotted line; n 5) rats. The values are the means S.E. *, p 0.05; **, p 0.01.
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